PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totalling 4,270,000 shares, a decline of 18.2% from the September 15th total of 5,220,000 shares. Based on an average trading volume of 623,500 shares, the days-to-cover ratio is currently 6.8 days.
Insiders Place Their Bets
In other PTC Therapeutics news, CFO Pierre Gravier sold 2,269 shares of the business’s stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $34.02, for a total transaction of $77,191.38. Following the completion of the transaction, the chief financial officer now owns 53,531 shares of the company’s stock, valued at approximately $1,821,124.62. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.50% of the company’s stock.
Hedge Funds Weigh In On PTC Therapeutics
A number of institutional investors have recently modified their holdings of PTCT. Allspring Global Investments Holdings LLC acquired a new position in shares of PTC Therapeutics during the first quarter worth approximately $46,000. CWM LLC raised its position in PTC Therapeutics by 354.7% in the 3rd quarter. CWM LLC now owns 2,687 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 2,096 shares during the last quarter. Quest Partners LLC purchased a new stake in PTC Therapeutics in the 2nd quarter valued at $128,000. Quarry LP raised its position in PTC Therapeutics by 100.0% in the 2nd quarter. Quarry LP now owns 5,000 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 2,500 shares during the last quarter. Finally, Lazard Asset Management LLC raised its position in PTC Therapeutics by 268.9% in the 1st quarter. Lazard Asset Management LLC now owns 6,504 shares of the biopharmaceutical company’s stock valued at $188,000 after buying an additional 4,741 shares during the last quarter.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Report on PTC Therapeutics
PTC Therapeutics Stock Performance
Shares of PTCT opened at $39.00 on Monday. PTC Therapeutics has a 52-week low of $17.53 and a 52-week high of $41.81. The business’s 50 day moving average price is $34.59 and its two-hundred day moving average price is $33.19. The firm has a market cap of $2.99 billion, a PE ratio of -5.08 and a beta of 0.65.
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.16). The firm had revenue of $186.70 million during the quarter, compared to the consensus estimate of $192.12 million. Research analysts predict that PTC Therapeutics will post -5.09 EPS for the current fiscal year.
PTC Therapeutics Company Profile
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Read More
- Five stocks we like better than PTC Therapeutics
- Energy and Oil Stocks Explained
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- Stock Average Calculator
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- What is the Shanghai Stock Exchange Composite Index?
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.